Suppressing Inflammation by Inhibiting the NF-κB Pathway Contributes to the Neuroprotective Effect of Angiotensin-(1-7) in Rats with Permanent Cerebral Ischaemia
Overview
Authors
Affiliations
Background And Purpose: Angiotensin-(1-7) [Ang-(1-7)] has anti-inflammatory effects in peripheral organs, but its effects in ischaemic stroke are unclear as yet. We investigated whether its anti-inflammatory effect contributes to the neuroprotection induced by Ang-(1-7) in a rat model of permanent middle cerebral artery occlusion (pMCAO).
Experimental Approach: We infused Ang-(1-7), Mas receptor antagonist A-779, angiotensin II type 2 receptor antagonist PD123319 or artificial CSF into the right lateral ventricle of male Sprague-Dawley rats from 48 h before onset of pMCAO until the rats were killed. Twenty-four hours after pMCAO, the neuroprotective effect of Ang-(1-7) was analysed by evaluating infarct volume and neurological deficits. The levels of oxidative stress were detected by spectrophotometric assay. The activation of NF-κB was assessed by Western blot and immunohistochemistry analysis. The level of COX-2 was tested by Western blot analysis and concentrations of pro-inflammatory cytokines were measured by elisa.
Key Results: Infusion of Ang-(1-7), i.c.v., significantly reduced infarct volume and improved neurological deficits. It decreased the levels of oxidative stress and suppressed NF-κB activity, which was accompanied by a reduction of pro-inflammatory cytokines and COX-2 in the peri-infarct regions. These effects of Ang-(1-7) were reversed by A-779 but not by PD123319. Additionally, infusion of A-779 alone increased oxidative stress levels and enhanced NF-κB activity, which was accompanied by an up-regulation of pro-inflammatory cytokines and COX-2.
Conclusion And Implications: Our findings indicate that suppressing NF-κB dependent pathway via Mas receptor may represent one mechanism that contributes to the anti-inflammatory effects of Ang-(1-7) in rats with pMCAO.
Ye D, Liu J, Lin L, Hou P, Feng T, Wang S PLoS One. 2024; 19(5):e0303150.
PMID: 38728304 PMC: 11086881. DOI: 10.1371/journal.pone.0303150.
Deng X, Ren J, Chen K, Zhang J, Zhang Q, Zeng J J Neuroinflammation. 2024; 21(1):106.
PMID: 38658922 PMC: 11041011. DOI: 10.1186/s12974-024-03105-8.
Hoyer-Kimura C, Hay M, Konhilas J, Morrison H, Methajit M, Strom J Aging Dis. 2023; 15(4):1927-1951.
PMID: 37815905 PMC: 11272189. DOI: 10.14336/AD.2023.0928.
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control.
Youssef M, Yahya G, Popoviciu M, Cavalu S, Abd-Eldayem M, Saber S Int J Mol Sci. 2023; 24(7).
PMID: 37047011 PMC: 10094124. DOI: 10.3390/ijms24076039.
COVID-19: Mechanisms, risk factors, genetics, non-coding RNAs and neurologic impairments.
Gilyazova I, Timasheva Y, Karunas A, Kazantseva A, Sufianov A, Mashkin A Noncoding RNA Res. 2023; 8(2):240-254.
PMID: 36852336 PMC: 9946734. DOI: 10.1016/j.ncrna.2023.02.007.